Vertex shares fell in after-hours trading, as investors considered a stock trading near its all-time high with a longer wait ...

One positive sign was that Vertex raised the lower end of its forecast for full-year 2025 revenue by $100 million. The ...

The cell and gene therapy space in recent months has hit several speedbumps, including layoffs, dropped drugs and ...

Vertex also picked up a positive Committee for Medicinal Products for Human Use (CHMP) opinion for Alyftrek. As a result, it's looking for European Commission approval for the drug in the second half ...

Vertex has recorded some 25,000 prescriptions for Journavx since its January approval and is in the process of getting big ...

Vertex Pharmaceuticals missed first-quarter profit and revenue forecasts as costs jumped. The biotech firm also posted a decline in sales outside the U.S. because of intellectual property rights ...

Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. The sharp decline came after the company announced its 2025 first-quarter results on Monday evening.